Coping Strategies, Loneliness, and Resilience in Patients With Dermatosis

Summary

The European Society for Dermatology \& Psychiatry (ESDaP) studies the connection between the skin and the mind. Two previous studies of this type were conducted in 13 and 15 European countries, respectively. The first study assessed the psychological impact of skin diseases (anxiety, depression, sleep disorders), and the second analyzed feelings of stigma, stress, and body dysmorphic disorder (an abnormal perception of one's body).

In this study, new psychological variables will be examined: coping strategies, loneliness, and resilience.

A total of 23 centers will participate in the ESDaP3 study, located in 15 European countries (Austria, France, Germany, Hungary, Italy, North Macedonia, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Turkey, and the United Kingdom).

The aim of this study is to examine coping strategies, loneliness, and resilience among patients with a skin condition. Coping strategies refer to the various ways a person uses to manage a difficult or stressful situation. Resilience refers to a person's ability to cope with difficult situations, adapt to changes or challenges, and regain a sense of balance despite obstacles. Other factors will be assessed: sleep, anxiety and depression, and quality of life. A questionnaire will be given to your potential partner to assess the impact of the skin condition on their life at this time.

At the study's sole French site, Brest University Hospital, 250 patients with a skin condition and 125 people without a skin condition will be enrolled.

Conditions

• Skin Disease
• Skin Disorder
• Skin Condition
• Inflammatory Skin Conditions
• Autoimmune Skin Diseases
• Cancerous Skin Conditions
• Genetic Skin Conditions

Interventions

OTHER

Questionnaires

* Coping strategies: Brief COPE questionnaire (dispositional format) * Loneliness: UCLA Loneliness Scale (ULS-8) * Resilience: Brief Resilience Scale (BRS) * Sleep: Insomnia Severity Index Questionnaire (ISI) * Anxiety: Generalized Anxiety Disorder 2 (GAD-2) * Depression: Patient Health Questionnaire-2 (PHQ-2) * Quality of life: Dermatology Life Quality Index (DLQI) * Well-being: Skin Well-Being Scale * Impact of dermatosis on the partner: FROM-16

Sponsors & Collaborators

• University of Graz

  collaborator OTHER

• Justus-Liebig University Gießen Medical Center

  collaborator UNKNOWN

• Szeged University

  collaborator OTHER

• University of Skopje

  collaborator OTHER

• University of Amsterdam

  collaborator OTHER

• University of Stavanger

  collaborator OTHER

• University of Bergen

  collaborator OTHER

• Wroclaw Medical University

  collaborator OTHER

• University of Rzeszow

  collaborator OTHER

• Universidade do Algarve

  collaborator OTHER

• Universidad de Zaragoza

  collaborator OTHER

• University of La Laguna

  collaborator OTHER

• Malmö University

  collaborator OTHER

• Lund University

  collaborator OTHER

• Karolinska Institutet

  collaborator OTHER

• Sisli Hamidiye Etfal Training and Research Hospital

  collaborator OTHER

• Cardiff University

  collaborator OTHER

• University Hospital Muenster

  collaborator OTHER

• Leiden University Medical Center

  collaborator OTHER

• The Royal London Hospital, UK

  collaborator UNKNOWN

• University Hospital, Brest

  lead OTHER

Study Design

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2026-07-31

Primary Completion

2029-07-31

Completion

2029-10-31

Countries

• France

Study Locations